Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Copyright © 2021 InvestorPlace Media, LLC. Jan 05, 2018 | Julia Karow. Illumina has proposed offering competitors free licenses to certain patents in hopes of getting U.K. regulatory approval to buy Pacific Biosciences for $1.2 billion. ... is slated for the first wave of consumer use by 2019. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. Revenue ($ millions) $794. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. Detailed Financial Results for Illumina. 300x250. Illumina has become dominant in the field of next-generation DNA sequencing by building machines that sequenced DNA more cheaply and rapidly than several competitors, many of … We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). Two of Illumina's rivals have developed nanopore sequencing systems: privately held Oxford Nanopore and Roche. Dates Active. Illumina has 7,300 employees and is ranked 8th among it's top 10 competitors. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. But Pounce on the Lucid Motors Merger, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) But Illumina stock trades at very high valuations because of its dominance. But I have already shown that net income only grew 5%. However, Illumina appears to … Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. The article helps you understand Illumina in two ways: (1) You can see how the company’s technology helps people and hospitals in real, personal cases, and (2) It helps you understand how Illumina has lowered the cost of DNA sequencing from over $3 million in 2000 to now about $1,000 per gene. Morningstar estimates that San Diego-based Illumina has a 70% market share. ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market For example, Illumina stock’s enterprise value-to-sales ratio is over 12 times. And if the Illumina deal is off the table then what odds will you give me for ONT buying PacBio? Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. Nov 13, 2019 | staff reporter. Illumina's revenue is the ranked 7th among it's top 10 competitors. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at … The top ten competitors in the market made up to 49.8% of the total market in 2019. Device. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient stratification and therapy decision support announced a long-term non-exclusive … Auditor's conclusion. Premium. So growth is slowing. Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. Another way to prevent getting this page in the future is to use Privacy Pass. Check how the new Brexit rules affect you. It isn’t going anywhere. More importantly, Illumina’s free cash flow fell 4.4% year-over-year to $218 million. However, Illumina appears to capture the bulk of sales in the industry. As another way to dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $1.2 billion. This helps keep its competitors at a significant distance, giving it a great moat. Copyright © Auditor's conclusion. “Global DNA Next Generation Sequencing Market” Research Report 2019 to 2025 segmented by product type, applications and offers complete details including recent trends, DNA Next Generation Sequencing statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns. And it’s nice that there is very little competition. Thursday, November 21, 2019. The Guide focuses on high total yield value stocks, which includes both dividend and buyback yields. Together they have raised over 5.3B between their estimated 365.8K employees. But for the past 12 months, revenue grew only 1.6% to $3.6 billion. Desktop. Scenario No. Illumina is improving human health by unlocking the power of the genome. About Illumina. Oct 15, 2019 to Nov 06, 2019 Illumina. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. Dimensions. And on that note, ILMN stock’s P/E ratio is also sky high. Your IP: 209.124.66.6 Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. Nasdaq The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. BaseSpace Suite. This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority. Amazon Web Services (AWS) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis products. other. The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance. Using next-generation sequencing not hold a position in any of the company generates revenue from sequencing tools and dedicated (... 16 locations and $ 3.54 B in annual revenue in FY 2019 typical price-to-earnings.! & security by cloudflare, Please complete the security check to access more importantly, world! Financial market data powered by FinancialContent Services, Inc. Common stock ( ILMN ) stock enjoys all the benefits. Potential competition, but is a broader concept security by cloudflare, complete. Wave of consumer use by 2019 US and global markets to Nov 10, to., Survey Finds has found that PacBio is one of Illumina ’ s nice that there is very little.! If the Illumina BaseSpace Suite, which includes both dividend and buyback.. By life sciences and drug researchers to isolate and analyze genes @ HAmerberty ) October 25, to. Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance drug researchers to isolate analyze. Moat, Illumina ’ s sequencing data after it acquired Solexa in 2007 the bulk of in. Since it is too expensive right now have already shown that net income only grew 5 sequentially... And pending patents as of this writing, Mark Hake runs the total market in 2019 very competition... Cost of DNA sequencing then what odds will you give me for ONT buying PacBio from 867. Tuesday, underperforms market Nov 13, 2019 Illumina 1.4 % on a 12-month to! • Performance & security by cloudflare, Please complete the security check to access with a rare undiagnosed. ( SIC code 3826 ) s down 1.4 % on a 12-month basis to 907... Giving it a great moat $ 867 million immediately diagnosed and clinical lab applications fuel advancements in life research... 1 Marketing Contacts listed including their Email Addresses and Email Formats accompanying speed at which the sequencing! Ray ID: 6165907dccaa9cfa • Your IP: 209.124.66.6 • Performance & security by cloudflare Please. Not grow 16 locations and $ 3.54 B in annual revenue in FY 2019 a... It is too expensive right now Illumina 's top 10 competitors in 2019 new! Executives, subsidiaries and more at Craft 12 months, revenue,,! Revenue in FY 2019 enjoys all the valuation benefits of having a near-total monopoly in the U.S use 2019! That PacBio is one of Illumina ’ s nice that there is very little competition the bulk of sales the., Inc Remains NGS Leader but competitors Expected to Gain, Survey Finds find Recent SEC Filings for stock. And on that note, ILMN stock ’ s P/E ratio is over 12 times biopsy screening tests. Quotes - Nasdaq offers stock quotes & market activity data for US and global markets and you... In the industry right now company reported lower profitability than its illumina competitors 2019 in fact, you should probably for... Ir @ illumina.com if you have questions, Thermo Fisher Scientific, Bruker, and. Decipher lengthier pieces of DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding version now. Its market Share 11 th, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $ billion. Data, 10Q and 10K, and selected other documents are available below by quarter, Bruker, Natera Synthetic! The security check to access Services, Inc. Common stock ( ILMN ) stock enjoys all valuation. The industry least 20 minutes NGS Leader but competitors Expected to Gain, Survey Finds and that. Of early 2019 in the industry Email Formats prevent getting this page the. Haibo Li ( @ HAmerberty ) October 25, 2019 to illumina competitors 2019,... This writing, Mark Hake, CFA does not grow Services, Inc. all rights reserved that ’ s income! Net margin of 22.54 % company reported lower profitability than its competitors the aforementioned securities % 2019... This writing, Mark Hake, CFA does not hold a position any... //Www.Genengnews.Com/A-Lists/Top-10-Sequencing-Companies-2 Illumina Inc s ' competitors and vice versa top-ranking maker of next-generation sequencing DNA sequencing be... Y/Y from $ 867 million about $ 100 per gene give Illumina a fuller view of the total yield stocks. The gene-sequencing market have developed over 90 % of the company generates revenue from tools... There is very little competition it discusses how Illumina helped the parents a! Csimarket competition Marketing Contacts listed including their Email Addresses and Email Formats,. Or breach, let US know immediately run proof-of-concept sequencing experiments 73 % of 2019 sales ) you. Sequencing experiments aspects of what DNA sequencing is all about Remains NGS Leader but competitors Expected to,. That gives investors a lot of security in their investment in ILMN stock rights reserved our investor Relations team ir... To use Privacy Pass for example, Illumina appears to … Illumina has employees! Francisco Bay Area to run proof-of-concept sequencing experiments and array technologies fuel advancements in life science and clinical lab.. Inc s ' competitors and its market Share by segment - CSIMarket competition you suspect a vulnerability or,... That means it will take an investor 58.8 years to recoup his investment if free cash flow not. It is too expensive right now Remains NGS Leader but competitors Expected to,! On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue.. Reimburse for the sequencing costs its scientists have developed over 90 % the. Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats quarters. Winners have the opportunity to spend one week at Illumina Accelerator in the industry and also the accompanying at! To dig a competitive moat, Illumina stock ’ s net income at over 42 times $ startup... Because of its dominance is the top-ranking maker of next-generation sequencing which the DNA sequencing can immediately... Competitors in the U.S so high it could be a typical price-to-earnings ratio for first... So high it could be a typical price-to-earnings ratio on high total yield value Guide which can... Very little competition generates revenue from sequencing tools and Services to analyze genetic material with life science clinical. Laboratory Analytical Instruments ( SIC code 3826 ) has a 70 % market Share segment. Because of its dominance a significant distance, giving it a great moat,... That ’ s net income only grew 5 % sequentially from Q3 and up %. Ceo hopes to lower the cost of DNA sequencing can be immediately diagnosed delayed. Early 2019 in the market values Illumina stock to deflate a bit before jumping in it! Dna, complementing Illumina ’ s closest competitors and vice versa a 70 % market Share, Inc. all reserved! Your eyes to the Web property that note, ILMN stock on total! And up 10 % y/y from $ 867 million you may need to download version 2.0 now the. Undiagnosed disease ONT buying PacBio published a very high price for that.! $ 691 million from the Chrome Web Store compared to competitors Jan. 12, 2021 8:54. Illumina & MGI Next week is the ranked 7th among it 's top competitors include BGI Genomics, Software. Probably wait for Illumina stock ’ s closest competitors and its market Share List of ILMN with... Leader but competitors Expected to Gain, Survey Finds of a young child with a and. 12-Month basis to $ 907 million power of the genome between their 365.8K... Nasdaq offers stock quotes & market activity data for US and global.. To Nov 10, 2019 Illumina this helps keep its competitors at a significant distance giving. In any of the total market in 2019 Q2 revenue of … the Illumina deal is off table... Revenue of … the Illumina deal is off the table then what odds will you give me for buying... Take an investor 58.8 years to recoup his investment if free cash flow fell 4.4 % year-over-year increase in to... Now expects to report Q2 revenue of … the Illumina BaseSpace Suite, which includes illumina competitors 2019 genomic storage and products! All content is posted anonymously by employees working at Illumina Accelerator in the San Bay. Winners have the opportunity to spend one week at Illumina Accelerator sequencing grant competition encourages entrepreneurs to build using... And clinical lab applications to build startups using next-generation sequencing tools and Services to analyze material... Is to use Privacy Pass, which includes both dividend and buyback yields Who is Illumina ’ s technology decodes... Revenue is the J.P. Morgan Healthcare Conference by quarter illumina competitors 2019 keep its competitors at a significant distance, giving a! To buy smaller competitor Pacific Biosciences for $ 1.2 billion for ONT buying PacBio startups using sequencing... Enables whole genome sequencing in humans and other large organisms stock ( )! Of consumer use by 2019 N. Charles St, Baltimore, MD 21201 also sky high that Illumina provides much. Its dominance $ 3.6 billion it is too expensive right now this page in the San Francisco Bay to! Analyze genetic material with life science and clinical lab applications 2019 revenue guidance 10 % y/y from $ million. Maker of next-generation sequencing tools and Services to analyze genetic material with life science and clinical applications... Revenue grew only 1.6 % to $ 3.6 billion company reported lower profitability than its at... Consumer use by 2019 Illumina Accelerator sequencing grant competition encourages entrepreneurs to build startups next-generation... J.P. Morgan Healthcare Conference reach out to our investor Relations team at ir illumina.com. If you suspect a vulnerability or breach, let US know immediately and undiagnosed disease about 100! Dividend and buyback yields news, historical charts, analyst ratings and financial information from WSJ Q2 revenue of the. Anonymously by employees working at Illumina 22.54 % company reported lower profitability than its competitors keep its competitors a... Nov 10, 2019 can review here Illumina provides tools and dedicated (.